Non-small cell lung cancer
RecruitingStudy comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression
Study comparing rilvegostomig plus chemotherapy versus pembrolizumab plus chemotherapy for first-line treatment in patients with metastatic non-squamous lung cancer with PD-L1 expression
- Disease:Non-small cell lung cancer
- Substances:CarboplatinCisplatin+5
France- Participants:18–64 years · 65+ years
- Substances:Carboplatin
- Sponsor:AstraZeneca AB











